Table 2 Analysis of enrichment of KEGG pathways and involved genes against menthol-flavored e-liquids.
Name | Involved genes | p-value |
|---|---|---|
Arginine and proline metabolism | PYCRL, CKMT1A, ALDH7A1, CKMT1B, SRM, ALDH1B1, GAMT, NOS3, PRODH, CKB | 0.000 |
Metabolic pathways | YP24A1, CKMT1B, PTGS2, CYC1, CAD, GPAT3, GLDC, CKB, AKR1C3, TRAK2, NOS3, PLCB2, IMPDH2, CYP1A1, PFKL, HKDC1, ALDH3B2, NME4, ALDH7A1, MGAT3, ALDH1B1, AKR1B10, ABAT, SLC27A5, PRODH, ALOX12, ME1, PYCRL, GCNT3, GCNT2, GCLC, AHCY, SORD, ASS1, SRM, GPAA1, UPP1, ASNS, ATP5G1, GCLM, PFAS, TYMP, DGKG, FASN, PNPO, HSD17B3, GALNT18, PNLIPRP3, B4GALNT1, HSD17B8, ST6GAL1, B4GALT2, APRT, CKMT1A, GCK, NDUFV1, GFPT1, POLD1, CSGALNACT2, PLCG2, POLD2, SMPD1, GAMT, CYP4F3, GK, RDH16, NNMT | 0.000 |
Bladder cancer | TYMP, FGFR3, MMP9, HBEGF, THBS1, MYC, MMP1 | 0.003 |
Inflammatory mediator regulation of TRP channels | TRPV3, PLCG2, ASIC3, ASIC1, MAPK10, CALML5, PLCB2, ITPR1, PIK3R2, ALOX12 | 0.013 |
ECM-receptor interaction | COL4A2, LAMB3, LAMA5, LAMC3, TNC, HSPG2, AGRN, ITGA4, THBS1 | 0.007 |
Proteoglycans in cancer | CAV1, WNT10B, TFAP4, MMP9, HSPG2, FLNC, ITPR1, CTSL, SMO, ANK1, PLCG2, HBEGF, THBS1, MYC, PIK3R2 | 0.013 |
Glycerolipid metabolism | ALDH7A1, ALDH1B1, AKR1B10, DGKG, GK, GPAT3, PNLIPRP3 | 0.018 |
Steroid hormone biosynthesis | AKR1C3, AKR1C2, CYP1A1, HSD11B2, HSD17B3, AKR1C1, HSD17B8 | 0.018 |
Galactose metabolism | B4GALT2, PFKL, GCK, HKDC1, AKR1B10 | 0.022 |
beta-Alanine metabolism | ALDH7A1, SRM, ALDH1B1, ABAT, ALDH3B2 | 0.024 |
Mineral absorption | HMOX1, MT1B, MT1X, FTH1, FTL, MT1F | 0.024 |
Small cell lung cancer | TRAF1, COL4A2, LAMB3, PTGS2, LAMA5, LAMC3, MYC, PIK3R2 | 0.034 |
Focal adhesion | COL4A2, CAV1, TNC, ITGA4, MAPK10, FLNC, LAMB3, LAMA5, CCND2, LAMC3, RAC3, THBS1, PARVB, PIK3R2 | 0.036 |
Alanine, aspartate and glutamate metabolism | ASS1, GFPT1, ABAT, CAD, ASNS | 0.036 |
